血清三种肿瘤标志物检测对胰腺癌诊断的意义  

Detection of the diagnosis about pancreatic cancer with the 3 tumor markers in serum

作　　者：蒋敬庭[1] 吴昌平[1] 邓海峰[1] 吴骏[1] 季枚[1] 张红宇[1] 孙文辉[1] 陈国瑾[1] 吴爱珍[1] 

机构地区：[1]江苏省苏州大学附属第三医院肿瘤生物诊疗中心,常州213003

出　　处：《中华检验医学杂志》2003年第7期431-432,共2页Chinese Journal of Laboratory Medicine

基　　金：苏州大学医学发展基金项目 (EE 12 40 0 1)

摘　　要：目的　建立一种检测血清恶性肿瘤相关物质 (TSGF)、糖类抗原 2 4 2 (CA2 4 2 )和糖类抗原 19 9(CA19 9)并用以诊断胰腺癌的方法。方法　用生化比色法与酶免法分别检测 2 0 0名正常人、6 0例胰腺炎患者、4 1例恶性淋巴瘤患者及 85例胰腺癌患者的TSGF、CA2 4 2和CA19 9含量。结果TSGF、CA2 4 2和CA19 9的真阳性百分率与假阳性百分率之比 ,即似然比 (LR)。其中阳性似然比依次为 5 4、12 7和 6 6 ,阴性似然比依次为 0 10、0 19和 0 15。敏感性最高TSGF(91 8% ) ,特异性最高CA2 4 2 (93 5 % ) ,TSGF与CA19 9有效性相近。以 3项均为阳性诊断胰腺癌 :其敏感性为 77 6 % ,而特异性和阳性预测值皆为 10 0 %。结论　用TSGF、CA2 4 2和CA19 9联合诊断胰腺癌可提高特异性和有效性。 3项指标联合检测对胰腺癌的诊断有十分重要的意义。Objective To establish a analysis method about pancreatic cancer with the 3 tumor markers of the TSGF、CA242 and CA19-9 in serum. Methods To assay the content of TSGF, CA242 and CA19-9 about the normal 200, the pancreatitis 60,the malignant lymphoma 41 and the pancreatic cancer 85 with Colorimetry of Biochemistry and ELISA. Results It′s in a ratio of about true positive percent to false positive percent, was named likelihood ratio. The results display that TSGF, CA242 and CA19-9 their positive likelihood ratio priority are 5.4, 12.7 and 6.6, the negative likelihood ratio priority are 0.10, 0.19 and 0.15. the highest sensitivity and specificity of TSGF are 91.8% and 93.5%.TSGF is close to CA19-9 at the availability. In combined test, all of them positive and changed to 77.6%,100% and 100%. The level of TSGF and CA242 in head of pancreas cancer are extra highest in the part of all pancreas, body of pancreas and head of pancreas,but CA19-9 hasn′t to do with part of the pancreas. Conclusion It′s to elevate their sensitivity and specificity in combination with TSGF, CA242 and CA19-9 to diagnose about pancreatic cancer .Their expressions what important function an act of diagnosing the pancreatic cancer.

关 键 词：血清 肿瘤标志物 检测 胰腺癌 诊断 恶性肿瘤相关物质 糖类抗原242 糖类抗原19-9 

分 类 号：R735.9[医药卫生—肿瘤] R730.43[医药卫生—临床医学]